Hospital Beata Maria Ana

Madrid 73 trials 41 recruiting

73 Registered trials

41 Currently recruiting

Organisation

Hospital Beata Maria Ana

Location

Madrid, Spain

Identifier

ORG-100048975

Address

Calle Del Doctor Esquerdo No. 83, 28007, Spain

Departments

#034003 Oncology
#03403 :Oncología medica
Hematology
IOB Madrid Institute of Oncology
Medical Oncology
Medical Oncology Department
N/A
Oncología
Oncologia Medica
Oncology
Oncology Department
Servicio de Oncologia
Servicio de Oncología Médica
Unidad de Cáncer de Mama
Unidad Oncologica Medica

Clinical trials at this site (73)

Search interface

A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtec… Ended

2023-507306-13-00 HER2-positive unresectable locally recurrent or metasta 4 2025-04-13
ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors Ended

2023-509716-29-00 Solid Tumors, Colorectal Cancer and Breast Cancer 9 2024-09-23
Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low Breast Cancer Patients Presenting with Newly Diagnosed or Progressing… Ended

2023-506702-39-00 HER2-low breast cancer presenting with newly diagnosed 4 2024-06-05
A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs ar… Ended

2023-508459-37-00 HER2-positive advanced solid tumours 1 2024-05-28
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15
A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended

2023-507333-17-00 HER2-low, Hormone Receptor Positive, Metastatic Breast 5 2024-04-15
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Ended

2022-502593-17-00 Locally advanced or metastatic hormone receptor (HR)-po 5 2023-09-19
Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended

2022-502145-10-00 Hormone Receptor (HR)-Positive, Human Epidermal Growth 5 2023-06-06
PHASE II STUDY FOR PATIENTS WITH ADVANCED TRIPLE NEGATIVE OR METAPLASTIC HRPOSITIVE/HER2-NEGATIVE, PIK3CA/PTEN-ALTERED BREAST CANCER TREATED… Ended

2024-512963-30-00 Locally advanced or unresectable PIK3CA and/or PTENalte 4 2023-05-24
A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer (… Ended

2023-509260-25-00 Locally Recurrent Inoperable or Metastatic Triple-negat 5 2022-07-12
Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Ended

2023-508738-32-00 Previously untreated and histologically confirmed HER2- 4 2021-06-16
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended

2023-507263-19-00 Advanced Non-Small Cell Lung Cancer 5 2020-12-23
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2… Ended

2023-505042-25-00 Locally advanced (inoperable) or metastatic HR+/HER2 br 5 2020-05-05
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 5 2018-12-27
PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF DEBIO 0123 AND SACITUZUMAB GOVITECAN IN TNBC OR HR+/HER2- ADVANCED/ METASTATIC BREAST C… Halted

2024-516322-60-00 TRIPLE-NEGATIVE OR HR+/HER2– ADVANCED/METASTATIC BREAST 9 2025-01-17
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo®… Ended

2023-507865-24-00 Advanced (unresectable/metastatic) melanoma 5 2025-03-28
Phase 2 Study of BB-1701 in HER2 positive or HER2-low metastatic breast cancer Ended

2023-506866-30-00 HER2 positive or HER2-low metastatic breast cancer 4 2024-08-19
A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HE… Ended

2023-503251-10-00 Metastatic Breast Cancer or Advanced Non-Small Cell Lun 4 2023-10-10
PREOPERATIVE WINDOW OF OPPORTUNITY STUDY WITH GIREDESTRANT (GDC-9545) OR TAMOXIFEN IN PREMENOPAUSAL WOMEN WITH ER[+]/HER2[-] & KI67≥10% EARL… Ended

2023-503565-36-00 ER[+]/HER2[-] & Ki67≥10% early breast cancer (EBC) 4 2023-07-19
A Phase 1b Trial of ARV-471 in Combination with Everolimus in Patients with ER+, HER2– Advanced or Metastatic Breast Cancer Ended

2024-513284-30-00 ER+, HER2– Advanced or Metastatic Breast Cancer 3 2023-03-22
GEN1047 for Solid Tumors - First in Human (FIH) Trial Ended

2024-510722-10-00 Malignant Solid Tumors 7 2021-12-13
A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended

2023-509591-42-00 HR-positive/HER2-negative breast cancer 4 2021-05-04
Study to evaluate the effect of metformin in the prevention of hyperglycemia in HR[+]/HER2[–] PIK3CA-mutated advanced breast cancer patients… Ended

2024-511295-33-00 Study to evaluate the effect of metformin in the preven 4 2020-08-13